Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulmozyme in COVID-19 ARDS
NCT04402944Phase 2Unknown
- Sponsor
- Boston Children's Hospital
- Start
- Jul 2020
- Primary completion
- Dec 2021
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of dornase alfa in COVID-19 pneumonia, acute respiratory distress syndrome (ARDS), sponsored by Boston Children's Hospital. Status: unknown.
02
Drugs
dornase alfa
03
Conditions
COVID-19 pneumoniaacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04402944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04402944.